[Generation and analyses of transgenic mice containing mutant p53 transgene]
- PMID: 10339928
[Generation and analyses of transgenic mice containing mutant p53 transgene]
Abstract
p53 is known to be a suppressor oncogene product regulating the cell cycle as a check point protein. Loss of function mutations were frequently observed in various human cancers. To investigate the role of mutant form of p53 in the presence of wild-type p53 in vivo, we generated two types of transgenic mice carrying p53 transgenes with mutation at the codon 248 from Arg to Trp or at the codon 249 from Arg to Ser. We obtained seven transgenic mouse lines with Trp-mutant type and eight lines from Ser-mutant type which express mutant p53 transgenes. These transgenic mice were observed for tumor formation over a period of one year. However, no tumors were developed within the monitoring period. To test whether the mutant p53 has a dominant negative effect on the wild type p53 or not, transgenic mice were crossed with p53 knockout mice which were heterozygous for the endogenous wild type p53 gene. Lymphocytes of these mice were cultured after gamma irradiation to induce apoptosis. Viability of lymphocytes as well as fragmentation of DNAs were measured. Apoptosis of lymphocytes from p53 +/- mutant transgenic mice was not suppressed compared with lymphocytes from p53 +/- mice. From these results, the mutant p53 with point mutation at the codon 248 from Arg to Trp or at the codon 249 from Arg to Ser, has a loss of function mutation, but not a dominant negative mutation over the wild type p53.
Similar articles
-
Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.Cancer Res. 2003 Aug 1;63(15):4389-95. Cancer Res. 2003. PMID: 12907609
-
A human papillomavirus type 18 E6/E7 transgene sensitizes mouse lens cells to human wild-type p53-mediated apoptosis.Oncogene. 1997 Jun 26;14(25):2991-8. doi: 10.1038/sj.onc.1201155. Oncogene. 1997. PMID: 9223662
-
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2948-53. doi: 10.1073/pnas.052713099. Epub 2002 Feb 26. Proc Natl Acad Sci U S A. 2002. PMID: 11867759 Free PMC article.
-
Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.Fukuoka Igaku Zasshi. 2009 Jun;100(6):217-28. Fukuoka Igaku Zasshi. 2009. PMID: 19670804 Review.
-
The p53-deficient mouse: a model for basic and applied cancer studies.Semin Cancer Biol. 1996 Oct;7(5):269-78. doi: 10.1006/scbi.1996.0035. Semin Cancer Biol. 1996. PMID: 9110404 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous